Transthyretin Amyloid Cardiomyopathy Clinical Trial

Clinical Trial Finder Transthyretin Amyloid Cardiomyopathy Trials

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

See Locations Near You

Summary

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

View Full Description

Full Description

This pilot study will determine the efficacy of ION-682284 in reducing the amyloid deposit on the heart tissue compared to placebo.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

To participate in the ION-682884-CS2MRI sub-study, participants must meet all inclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).

Exclusion Criteria

Contraindication or sensitivity to MRI contrast agents
Orthopnea of sufficient severity to preclude supine scanning at screening.
Weight or body girth exceeds the limits of the cardiac MRI machine specifications.
Contraindication to cardiac MRI scanning, as assessed by local MRI safety questionnaire/checklist.

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

150

Study ID:

NCT06073574

Recruitment Status:

Active, not recruiting

Sponsor:

Ionis Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Brigham and Women's Hospital
Boston Massachusetts, 02115, United States
Oregon Health and Science University
Portland Oregon, 97239, United States
Azienda Ospedaliero - Universitaria Careggi
Florence , 50139, Italy
Azienda Ospedale Università di Padova
Padova , 35128, Italy
Hospital Universitario Puerta de Hierro
Majadahonda , 28222, Spain
Synexus - Scotland Clinical Research Centre
Bellshill , ML4 3, United Kingdom
Synexus Midlands Clinical Research Centre
Birmingham , B15 2, United Kingdom
Synexus - Wales
Cardiff , CF15 , United Kingdom
Royal Free London NHS Foundation Trust
London , NW3 2, United Kingdom
Richmond Pharmacology
London , SE1 1, United Kingdom
Synexus - Manchester Clinical Research Centre
Manchester , M15 6, United Kingdom
Load More

How clear is this clinincal trial information?

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

150

Study ID:

NCT06073574

Recruitment Status:

Active, not recruiting

Sponsor:


Ionis Pharmaceuticals, Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider